Aker BioMarine (OB:AKBM) - Prezzo delle azioni, notizie e analisi

AKBM Panoramica delle azioni

Aker BioMarine AS si occupa della raccolta del krill e fornisce prodotti derivati dal krill in tutto il mondo.

AKBM analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	3/6
Prestazioni passate	3/6
Salute finanziaria	4/6
Dividendi	2/6

Premi

Negoziato a 73% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 100.65% all'anno

È diventato redditizio quest'anno

Analisi del rischio

I pagamenti degli interessi non sono ben coperti dagli utili

Prezzo delle azioni altamente volatile negli ultimi 3 mesi

Aker BioMarine AS Concorrenti

Kaldvik

OB:KLDVK

NOK 3.3b

Måsøval

OB:MAS

NOK 3.4b

Austevoll Seafood

OB:AUSS

NOK 19.4b

Lerøy Seafood Group

OB:LSG

NOK 30.6b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Aker BioMarine
Prezzi storici delle azioni
Prezzo attuale dell'azione	NOK 47.65
Massimo di 52 settimane	NOK 109.80
Minimo di 52 settimane	NOK 39.55
Beta	0.88
1Variazione di 1 mese	-1.75%
Variazione a 3 mesi	-50.42%
Variazione di 1 anno	13.45%
3Variazione a 3 anni	11.99%
Variazione a 5 anni	n/a
Variazione dall'IPO	-54.49%

Notizie e aggiornamenti recenti

Aker BioMarine AS' (OB:AKBM) Revenues Are Not Doing Enough For Some Investors

Nov 05

At kr102, Is It Time To Put Aker BioMarine AS (OB:AKBM) On Your Watch List?

Aug 20

Recent updates

Aker BioMarine AS' (OB:AKBM) Revenues Are Not Doing Enough For Some Investors

Nov 05

At kr102, Is It Time To Put Aker BioMarine AS (OB:AKBM) On Your Watch List?

Aug 20

Optimistic Investors Push Aker BioMarine AS (OB:AKBM) Shares Up 25% But Growth Is Lacking

Jul 19

What Does The Future Hold For Aker BioMarine AS (OB:AKBM)? These Analysts Have Been Cutting Their Estimates

Jul 16

There Are Reasons To Feel Uneasy About Aker BioMarine's (OB:AKBM) Returns On Capital

Jul 11

These 4 Measures Indicate That Aker BioMarine (OB:AKBM) Is Using Debt In A Risky Way

Jun 03

There's No Escaping Aker BioMarine AS' (OB:AKBM) Muted Revenues

Feb 15

There Are Reasons To Feel Uneasy About Aker BioMarine's (OB:AKBM) Returns On Capital

Nov 06

Estimating The Fair Value Of Aker BioMarine AS (OB:AKBM)

Sep 06

We Think You Should Be Aware Of Some Concerning Factors In Aker BioMarine's (OB:AKBM) Earnings

Nov 04

Aker BioMarine AS' (OB:AKBM) Has Found A Path To Profitability

Apr 13

Aker BioMarine AS (OB:AKBM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Feb 18

Loss-Making Aker BioMarine AS (OB:AKBM) Set To Breakeven

Jan 07

Rendimenti per gli azionisti

	AKBM	NO Food	NO Mercato
7D	-7.1%	-1.4%	-3.1%
1Y	13.5%	12.3%	0.8%

Ritorno vs Industria: AKBM ha avuto una performance inferiore rispetto al Norwegian Food che ha registrato un rendimento 12.3 % nell'ultimo anno.

Rendimento vs Mercato: AKBM ha superato il mercato Norwegian che ha restituito 0.8 % nell'ultimo anno.

Volatilità dei prezzi

Is AKBM's price volatile compared to industry and market?
AKBM volatility
AKBM Average Weekly Movement	13.8%
Food Industry Average Movement	5.0%
Market Average Movement	5.0%
10% most volatile stocks in NO Market	10.6%
10% least volatile stocks in NO Market	2.6%

Prezzo delle azioni stabile: Il prezzo delle azioni di AKBM è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale di AKBM è aumentata da 9% a 14% nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2006	373	Matts Johansen	www.akerbiomarine.com

Aker BioMarine AS si occupa della raccolta del krill e fornisce prodotti derivati dal krill in tutto il mondo. Opera attraverso due segmenti, Ingredienti e Marchi. Il segmento Ingredienti si occupa della raccolta e della produzione in mare aperto, delle operazioni logistiche e della produzione e vendita a terra di prodotti derivati dal krill per i settori della nutraceutica, del pet food e dell'acquacoltura.

Aker BioMarine AS Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Aker BioMarine con la sua capitalizzazione di mercato?
AKBM statistiche fondamentali
Capitalizzazione di mercato	NOK 4.18b
Guadagni(TTM)	NOK 28.79m
Ricavi(TTM)	NOK 3.71b

145.1x

Rapporto P/E

1.1x

Rapporto P/S

AKBM è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
AKBM Conto economico (TTM)
Ricavi	US$334.80m
Costo del fatturato	US$225.90m
Profitto lordo	US$108.90m
Altre spese	US$106.30m
Guadagni	US$2.60m

Ultimi guadagni dichiarati

Sep 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	0.03
Margine lordo	32.53%
Margine di profitto netto	0.78%
Rapporto debito/patrimonio netto	79.2%

Come si è comportato AKBM nel lungo periodo?

Vedi performance storica e confronto

Dividendi

94.4%

Rendimento attuale del dividendo

n/a

Rapporto di remunerazione

AKBM Panoramica delle azioni

Premi

Analisi del rischio

Aker BioMarine AS Concorrenti

OB:KLDVK

NOK 3.3b

OB:MAS

NOK 3.4b

OB:AUSS

NOK 19.4b

OB:LSG

NOK 30.6b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Aker BioMarine AS' (OB:AKBM) Revenues Are Not Doing Enough For Some Investors

New major risk - Financial position

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Share price stability

Aker BioMarine AS Announces Extraordinary Dividend, Payable on 30 September 2024

At kr102, Is It Time To Put Aker BioMarine AS (OB:AKBM) On Your Watch List?

Recent updates

Aker BioMarine AS' (OB:AKBM) Revenues Are Not Doing Enough For Some Investors

New major risk - Financial position

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Share price stability

Aker BioMarine AS Announces Extraordinary Dividend, Payable on 30 September 2024

At kr102, Is It Time To Put Aker BioMarine AS (OB:AKBM) On Your Watch List?

Optimistic Investors Push Aker BioMarine AS (OB:AKBM) Shares Up 25% But Growth Is Lacking

What Does The Future Hold For Aker BioMarine AS (OB:AKBM)? These Analysts Have Been Cutting Their Estimates

Second quarter 2024 earnings released: US$0.03 loss per share (vs US$0.005 profit in 2Q 2023)

Aker BioMarine AS Expects to Pay Extraordinary Dividend

Aker BioMarine AS Expects to Pay Extraordinary Dividend

There Are Reasons To Feel Uneasy About Aker BioMarine's (OB:AKBM) Returns On Capital

Aker BioMarine Antarctic Holding II AS completed the acquisition of Feed Ingredients business of Aker BioMarine AS (OB:AKBM).

AIP, LLC and Aker Capital ASA agreed to acquire Feed Ingredients business from Aker BioMarine AS (OB:AKBM).

AIP, LLC and Aker Capital ASA agreed to acquire Feed Ingredients business from Aker BioMarine AS (OB:AKBM).

These 4 Measures Indicate That Aker BioMarine (OB:AKBM) Is Using Debt In A Risky Way

First quarter 2024 earnings released: US$0.07 loss per share (vs US$0.20 loss in 1Q 2023)

Consensus EPS estimates fall by 69%

Full year 2023 earnings: EPS exceeds analyst expectations

Full year 2023 earnings released: US$0.10 loss per share (vs US$0.11 profit in FY 2022)

There's No Escaping Aker BioMarine AS' (OB:AKBM) Muted Revenues

There Are Reasons To Feel Uneasy About Aker BioMarine's (OB:AKBM) Returns On Capital

Third quarter 2023 earnings released: US$0.01 loss per share (vs US$0.05 profit in 3Q 2022)

Aker BioMarine AS to Report Q1, 2024 Results on Apr 25, 2024

No independent directors

Aker BioMarine ASA Receives Approval for LYSOVETA as New Dietary Suppient in the US

Aker BioMarine AS Provides Revenue Guidance for the Full Year of 2023

Aker BioMarine AS Provides Revenue Guidance for the Full Year of 2023

Consensus EPS estimates fall from profit to US$0.086 loss, revenue upgraded

Full year 2022 earnings: EPS misses analyst expectations

Consensus EPS estimates increase by 308%

Consensus EPS estimates fall by 65%

Chairman recently bought kr5.4m worth of stock

Full year 2022 earnings: EPS misses analyst expectations

Aker BioMarine ASA Announces Ministry of Food and Drug Safety in South Korea Approves Superba Krill Oil

Chief Executive Officer recently bought kr305k worth of stock

No independent directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Consensus EPS estimates increase by 57%

Now 20% undervalued

Estimating The Fair Value Of Aker BioMarine AS (OB:AKBM)

Consensus EPS estimates increase by 136%

Consensus forecasts updated

Aker Biomarine as Reiterates Earnings Guidance for the Full Year of 2022

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Aker BioMarine AS Appoints Mr. Øyvind Eriksen as an Observer to the Board on June 8, 2022

Now 20% undervalued

Forecast breakeven date moved forward to 2022

Now 22% undervalued

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

No independent directors

Aker Biomarine AS Announces Board Changes

Full year 2021 earnings: EPS and revenues miss analyst expectations

Aker BioMarine AS, Annual General Meeting, Apr 20, 2022

Aker BioMarine AS, Annual General Meeting, Apr 20, 2022

Consensus forecasts updated

Forecast breakeven date moved forward to 2022

Forecast breakeven date moved forward to 2022